You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

EMBOLEX Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for EMBOLEX?
  • What are the global sales for EMBOLEX?
  • What is Average Wholesale Price for EMBOLEX?
Summary for EMBOLEX
US Patents:0
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 131
Clinical Trials: 1
DailyMed Link:EMBOLEX at DailyMed
Drug patent expirations by year for EMBOLEX
Recent Clinical Trials for EMBOLEX

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
NovartisPhase 3

See all EMBOLEX clinical trials

US Patents and Regulatory Information for EMBOLEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis EMBOLEX dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride INJECTABLE;INJECTION 018885-001 Nov 30, 1984 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Novartis EMBOLEX dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride INJECTABLE;INJECTION 018885-002 Nov 30, 1984 DISCN No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for EMBOLEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis EMBOLEX dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride INJECTABLE;INJECTION 018885-001 Nov 30, 1984 4,402,949 ⤷  Start Trial
Novartis EMBOLEX dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride INJECTABLE;INJECTION 018885-001 Nov 30, 1984 4,451,458 ⤷  Start Trial
Novartis EMBOLEX dihydroergotamine mesylate; heparin sodium; lidocaine hydrochloride INJECTABLE;INJECTION 018885-002 Nov 30, 1984 4,451,458 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EMBOLEX Market Analysis and Financial Projection

Last updated: February 14, 2026

Market Dynamics for EMBOLEX

EMBOLEX (ethambutol) is an antimicrobial drug primarily used in the treatment of tuberculosis (TB). Its market landscape is influenced by TB epidemiology, regulatory environment, competition, and global health initiatives.

Tuberculosis Epidemiology and Impact

TB remains a significant global health issue, with an estimated 10.6 million cases worldwide in 2021 (WHO). Resistance to first-line agents like rifampicin and isoniazid drives demand for second-line agents such as EMBOLEX. Multidrug-resistant TB (MDR-TB) cases account for roughly 17% of new TB cases globally, increasing reliance on alternative agents.

Regulatory Environment and Approvals

EMBOLEX has approvals in multiple regions, including the US, Europe, and parts of Asia. Ongoing regulatory updates, especially regarding safety profiles and pediatric indications, influence market access. The US FDA approved the drug since the 1970s, with periodic updates. WHO includes ethambutol in its non-compulsory TB treatment guidelines, influencing procurement policies.

Competitive Landscape

EMBOLEX faces competition mainly from other second-line anti-TB agents such as levofloxacin, moxifloxacin, and bedaquiline. These newer drugs often exhibit better resistance profiles and shorter treatment durations, affecting EMBOLEX's market share. Nevertheless, EMBOLEX remains essential due to its established safety profile and cost-effectiveness.

Manufacturing and Supply Chain

Major pharmaceutical companies and generic manufacturers produce EMBOLEX. Supply chain disruptions, especially during global health crises like COVID-19, have occasionally impacted availability in high-burden countries. Patents have expired in several jurisdictions, expanding generic production.

Market Drivers and Barriers

  • Drivers: Rising MDR-TB cases, inclusion in WHO treatment regimens, expanding clinical use in combination therapies.
  • Barriers: Development of resistance, side-effect profiles (notably optic neuropathy), competition from newer drugs, and regulatory hurdles in emerging markets.

Financial Trajectory of EMBOLEX

Revenue Estimates and Market Size

Global TB drug market size was valued at approximately $1.2 billion in 2022, with second-line agents like EMBOLEX comprising an estimated 10-15% of the segment. The immediate market for EMBOLEX is roughly $120 million to $180 million annually, predominantly in endemic regions such as India, China, and Southeast Asia.

Pricing and Reimbursement

Pricing varies significantly across regions. In countries with national TB programs, EMBOLEX is typically subsidized or provided at low cost. In high-income markets, prices range from $10 to $30 per tablet, with treatment courses involving 500 mg daily doses lasting 2-3 months.

R&D and Regulatory Investment

Investment in improving TB drugs like EMBOLEX involves clinical trials focusing on resistance management and adverse effect reduction. The global TB drug research budget allocated approximately $400 million annually, with a minor fraction dedicated specifically to ethambutol modifications.

Growth Opportunities and Forecasts

Market analysts forecast a compound annual growth rate (CAGR) of 2-3% for the EMBOLEX segment through 2030, driven mainly by MDR-TB treatment needs. Resistance development, however, poses a long-term risk potentially reducing market size if new, more effective agents supplant ethambutol.

Geographic Expansion and Market Penetration

Emerging markets with high MDR-TB prevalence exhibit the most growth potential. Increased global funding and partnerships with organizations like WHO expand access. Patent expirations assist generic manufacturers in lowering costs, boosting volume sales.

Risks and Challenges

  • Increasing resistance to ethambutol threatens long-term market viability.
  • Safety concerns, specifically optic neuropathy, could restrict use.
  • Military and political instability in key regions may impact supply chains and market stability.

Key Takeaways

  • EMBOLEX represents a critical component in MDR-TB management, but faces competition from newer agents.
  • The global TB drug market is expanding modestly, with continued reliance on established drugs like EMBOLEX.
  • Pricing, supply chain stability, and resistance trends are primary factors influencing financial trajectories.
  • Investment in R&D centers on resistance management and safety improvements, with limited direct funds dedicated to ethambutol-specific innovations.
  • Market growth is concentrated in high-burden, low-to-middle-income countries, with expanding access driven by international health initiatives.

FAQs

1. How does resistance impact EMBOLEX’s market?
Developing resistance reduces its effectiveness, potentially limiting use and prompting shifts to alternative drugs.

2. What are the main side effects influencing prescribing patterns?
Optic neuropathy and liver toxicity are primary concerns, especially with prolonged use.

3. How do patent statuses affect market competition?
Expired patents in key markets facilitate generic production, expanding access and lowering prices.

4. Are there efforts to improve EMBOLEX’s safety profile?
Yes, ongoing clinical trials explore dosage adjustment and combination therapies to mitigate adverse effects.

5. What is the outlook for EMBOLEX’s market share in the next decade?
Market share is expected to decline gradually due to competition from newer agents unless resistance develops or new formulations emerge.


References

  1. WHO Global Tuberculosis Report 2022.
  2. U.S. Food and Drug Administration, EMBOLEX approval history.
  3. Market research reports on TB therapeutics.
  4. Global Authority on TB drug resistance trends.
  5. Patent databases for ethambutol formulations.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.